SG/CALL/ELI LILLY & CO/1050/0.1/16.01.26 | Real-time Boerse Frankfurt Warrants 18:49:44 15/05/2024 BST | ||
| 6.23 EUR | +10.27% |
|
| Current month | -15.29% | ||
| 1 month | -8.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 15/05/24 | 6.23 | +10.27% |
| 14/05/24 | 5.65 | +2.36% |
| 13/05/24 | 5.52 | -2.99% |
| 10/05/24 | 5.69 | -5.64% |
| 09/05/24 | 6.03 | -3.21% |
Real-time Boerse Frankfurt Warrants
Last update May 15, 2024 at 06:49 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW8U9W |
| ISIN | DE000SW8U9W3 |
| Date issued | 10/04/2024 |
| Strike | 1,050 $ |
| Maturity | 16/01/2026 (611 Days) |
| Parity | 10 : 1 |
| Emission price | 6.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.81 € |
|---|---|
| Lowest since issue | 4.79 € |
| Spread | 0.09 € |
| Spread % | 1.43% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
- Stock Market
- Warrants
- Warrant
